FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361952912> ?p ?o ?g. }

• W4361952912 abstract "<div>AbstractPurpose:<p>Next-generation sequencing (NGS) can be used for comprehensive investigation of molecular events in breast cancer. We evaluated the relevance of genomic alterations for response to neoadjuvant chemotherapy (NACT) in the GeparSepto trial.</p>Experimental Design:<p>Eight hundred fifty-one pretherapeutic formalin-fixed paraffin-embedded (FFPE) core biopsies from GeparSepto study were sequenced. The panel included 16 genes for mutational (<i>AKT1, BRAF, CDH1, EGFR, ERBB2, ESR1, FBXW7, FGFR2, HRAS, KRAS, NRAS, SF3B1, TP53, HNF1A, PIK3CA</i>, and <i>PTEN</i>) and 8 genes for copy-number alteration analysis (<i>CCND1, ERBB2, FGFR1, PAK1, PIK3CA, TOP2A, TP53</i>, and <i>ZNF703</i>).</p>Results:<p>The most common genomic alterations were mutations of <i>TP53</i> (38.4%) and <i>PIK3CA</i> (21.5%), and 8 different amplifications (<i>TOP2A</i> 34.9%; <i>ERBB2</i> 30.6%; <i>ZNF703</i> 30.1%; <i>TP53</i> 21.9%; <i>PIK3CA</i> 24.1%; <i>CCND1</i> 17.7%; <i>PAK1</i> 14.9%; <i>FGFR</i> 12.6%). All other alterations had a prevalence of less than 5%. The genetic heterogeneity in different breast cancer subtypes [lum/HER2neg vs. HER2pos vs. triple-negative breast cancer (TNBC)] was significantly linked to differences in NACT response. A significantly reduced pathologic complete response rate was observed in <i>PIK3CA</i>-mutated breast cancer [<i>PIK3CA</i>mut: 23.0% vs. wild-type (wt) 38.8%, <i>P</i> < 0.0001] in particular in the HER2pos subcohort [multivariate OR = 0.43 (95% CI, 0.24–0.79), <i>P</i> = 0.006]. An increased response to nab-paclitaxel was observed only in <i>PIK3CA</i>wt breast cancer, with univariate significance for the complete cohort (<i>P</i> = 0.009) and the TNBC (<i>P</i> = 0.013) and multivariate significance in the HER2pos subcohort (test for interaction <i>P</i> = 0.0074).</p>Conclusions:<p>High genetic heterogeneity was observed in different breast cancer subtypes. Our study shows that FFPE-based NGS can be used to identify markers of therapy resistance in clinical study cohorts. <i>PIK3CA</i> mutations could be a major mediator of therapy resistance in breast cancer.</p></div>" @default.
• W4361952912 created "2023-04-05" @default.
• W4361952912 creator A5002077225 @default.
• W4361952912 creator A5002711674 @default.
• W4361952912 creator A5007997038 @default.
• W4361952912 creator A5008563937 @default.
• W4361952912 creator A5009743864 @default.
• W4361952912 creator A5011410319 @default.
• W4361952912 creator A5014883814 @default.
• W4361952912 creator A5016987068 @default.
• W4361952912 creator A5017728105 @default.
• W4361952912 creator A5018491022 @default.
• W4361952912 creator A5018744564 @default.
• W4361952912 creator A5024589782 @default.
• W4361952912 creator A5025517141 @default.
• W4361952912 creator A5026607584 @default.
• W4361952912 creator A5032626301 @default.
• W4361952912 creator A5033698551 @default.
• W4361952912 creator A5044330330 @default.
• W4361952912 creator A5054109395 @default.
• W4361952912 creator A5057181684 @default.
• W4361952912 creator A5058109622 @default.
• W4361952912 creator A5077307794 @default.
• W4361952912 creator A5087559224 @default.
• W4361952912 creator A5089035898 @default.
• W4361952912 creator A5089392438 @default.
• W4361952912 date "2023-03-31" @default.
• W4361952912 modified "2023-09-26" @default.
• W4361952912 title "Data from Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial" @default.
• W4361952912 doi "https://doi.org/10.1158/1078-0432.c.6527817.v1" @default.
• W4361952912 hasPublicationYear "2023" @default.
• W4361952912 type Work @default.
• W4361952912 citedByCount "0" @default.
• W4361952912 crossrefType "posted-content" @default.
• W4361952912 hasAuthorship W4361952912A5002077225 @default.
• W4361952912 hasAuthorship W4361952912A5002711674 @default.
• W4361952912 hasAuthorship W4361952912A5007997038 @default.
• W4361952912 hasAuthorship W4361952912A5008563937 @default.
• W4361952912 hasAuthorship W4361952912A5009743864 @default.
• W4361952912 hasAuthorship W4361952912A5011410319 @default.
• W4361952912 hasAuthorship W4361952912A5014883814 @default.
• W4361952912 hasAuthorship W4361952912A5016987068 @default.
• W4361952912 hasAuthorship W4361952912A5017728105 @default.
• W4361952912 hasAuthorship W4361952912A5018491022 @default.
• W4361952912 hasAuthorship W4361952912A5018744564 @default.
• W4361952912 hasAuthorship W4361952912A5024589782 @default.
• W4361952912 hasAuthorship W4361952912A5025517141 @default.
• W4361952912 hasAuthorship W4361952912A5026607584 @default.
• W4361952912 hasAuthorship W4361952912A5032626301 @default.
• W4361952912 hasAuthorship W4361952912A5033698551 @default.
• W4361952912 hasAuthorship W4361952912A5044330330 @default.
• W4361952912 hasAuthorship W4361952912A5054109395 @default.
• W4361952912 hasAuthorship W4361952912A5057181684 @default.
• W4361952912 hasAuthorship W4361952912A5058109622 @default.
• W4361952912 hasAuthorship W4361952912A5077307794 @default.
• W4361952912 hasAuthorship W4361952912A5087559224 @default.
• W4361952912 hasAuthorship W4361952912A5089035898 @default.
• W4361952912 hasAuthorship W4361952912A5089392438 @default.
• W4361952912 hasConcept C1167327 @default.
• W4361952912 hasConcept C121608353 @default.
• W4361952912 hasConcept C126322002 @default.
• W4361952912 hasConcept C190283241 @default.
• W4361952912 hasConcept C21790070 @default.
• W4361952912 hasConcept C2777609662 @default.
• W4361952912 hasConcept C2781187634 @default.
• W4361952912 hasConcept C502942594 @default.
• W4361952912 hasConcept C526805850 @default.
• W4361952912 hasConcept C530470458 @default.
• W4361952912 hasConcept C54355233 @default.
• W4361952912 hasConcept C71924100 @default.
• W4361952912 hasConcept C86554907 @default.
• W4361952912 hasConcept C86803240 @default.
• W4361952912 hasConceptScore W4361952912C1167327 @default.
• W4361952912 hasConceptScore W4361952912C121608353 @default.
• W4361952912 hasConceptScore W4361952912C126322002 @default.
• W4361952912 hasConceptScore W4361952912C190283241 @default.
• W4361952912 hasConceptScore W4361952912C21790070 @default.
• W4361952912 hasConceptScore W4361952912C2777609662 @default.
• W4361952912 hasConceptScore W4361952912C2781187634 @default.
• W4361952912 hasConceptScore W4361952912C502942594 @default.
• W4361952912 hasConceptScore W4361952912C526805850 @default.
• W4361952912 hasConceptScore W4361952912C530470458 @default.
• W4361952912 hasConceptScore W4361952912C54355233 @default.
• W4361952912 hasConceptScore W4361952912C71924100 @default.
• W4361952912 hasConceptScore W4361952912C86554907 @default.
• W4361952912 hasConceptScore W4361952912C86803240 @default.
• W4361952912 hasLocation W43619529121 @default.
• W4361952912 hasOpenAccess W4361952912 @default.
• W4361952912 hasPrimaryLocation W43619529121 @default.
• W4361952912 hasRelatedWork W2044351212 @default.
• W4361952912 hasRelatedWork W2152566353 @default.
• W4361952912 hasRelatedWork W2268032170 @default.
• W4361952912 hasRelatedWork W2517593763 @default.
• W4361952912 hasRelatedWork W2562055621 @default.
• W4361952912 hasRelatedWork W2790698431 @default.
• W4361952912 hasRelatedWork W2913983450 @default.
• W4361952912 hasRelatedWork W3179278744 @default.
• W4361952912 hasRelatedWork W4282965509 @default.
• W4361952912 hasRelatedWork W4384282730 @default.
• W4361952912 isParatext "false" @default.

• next